Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn:
“I am honored to have contributed, as investigator and author, to the MARIPOSA study, published today in the New England Journal of Medicine.
This is a significant milestone for the advancement and understanding of EGFR-mutated non-small-cell lung cancer (NSCLC).
The study demonstrated that the combination of amivantamab and lazertinib for the treatment of patients with advanced NSCLC harboring common EGFR mutations, achieved significantly longer progression-free survival compared to osimertinib.
This improvement, confirmed across all clinical and biological high-risk factors (with the analysis published concurrently today in the Annals of Oncology), establishes this combination as the new standard of care for first-line treatment. Additionally, the subcutaneous use of amivantamab, as presented in the PALOMA-3 study, further enhances this treatment approach.
For more details, you can read the full manuscripts here:
Source: Antonio Passaro/LinkedIn
Antonio Passaro MD PhD, a medical oncologist at the European Institute of Oncology in Milan, specializes in lung cancer research and treatment. he focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC). Dr. Passaro leads lung cancer trials, evaluates therapeutic efficacy and safety. Authoring over 100 peer-reviewed papers, he also holds editorial positions and key roles in societies like ESMO and AIOM. .